The Goldman Sachs technology M&A team, led by Sam Britton, has cashed in on its software focus and decades of experience to dominate 2019's biggest deals.Technologyread more
American small and medium-size companies that rely on China are scrambling to adjust their business plans in response to the escalating trade war.Traderead more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
The summit comes amid fears over a global economic slowdown, and U.S. tensions over trade allies, Iran and Russia.Politicsread more
The world's second biggest economy is past a point where it cannot ignore its enormous debt anymore, according to an analyst.China Economyread more
Carl Medlock used to work at Tesla. Now he's one of the few people in the U.S. that can fix the company's original Roadster electric vehicles.Technologyread more
Trump does have some powerful tools that would not require approval from U.S. Congress.Politicsread more
Stocks dropped after Donald Trump ordered that U.S. manufacturers find alternatives to their operations in China.US Marketsread more
As demand for lab monkeys continues to rise, U.S. scientists are reporting delays in research projects because they can't obtain enough animals, according to the National...Politicsread more
The European Union will respond in kind if the U.S. imposes tariffs on France over digital tax plan, EU chief Donald Tusk told G-7.Technologyread more
Trump said he will raise tariffs on $250 billion in Chinese goods to 30% and hike duties on another $300 billion in products to 15%.Politicsread more
A judge has unsealed records from a Kentucky lawsuit against the maker of the prescription painkiller OxyContin, including the secret testimony of a former company president.
Pike Circuit Court Judge Steven Combs ordered the records be released in 32 days. But Combs said he would delay his order if Purdue Pharma appealed the decision. Richard Silbert, the company's chief litigation counsel, confirmed it would appeal. He declined further comment.
OxyContin is a powerfully addictive prescription painkiller that was marketed for its ability to slowly release its effects over a 12-hour period. The company suggested this long-acting formula made it less addictive and safer for patients. But users quickly found the pill lost its time-release qualities if it was crushed, resulting in an instant high.
In 2006, the company agreed to plead guilty and pay more than $630 million to settle federal charges that it misled doctors and patients about the risks of its top-selling drug. The company released a new version of the drug in 2010 that they said deters abuse.
Kentucky was particularly affected by the drug, as it was prescribed to many injured coal miners in the eastern part of the state. In 2007, Kentucky's attorney general filed a separate lawsuit against Purdue Pharma. Both sides settled the case in December and the company agreed to pay Kentucky $24 million.
But the lawsuit generated more than 17 million pages of documents, including marketing strategies, training manuals, instructions to sales representatives and testimony from company officials. The records include a deposition of Dr. Richard Sackler, a former Purdue Pharma president and a member of the family that controls the company.
The judge in the case agreed to seal any records Purdue Pharma marked as confidential. Statnews.com, a health news website owned by Boston Globe owner John W. Henry, sued to have the records released once the case was resolved. They are particularly interested in Sackler's testimony, as it could reveal how much the company knew about how addictive OxyContin truly is.
Lawyers for Purdue Pharma said the company agreed to hand over documents and give Kentucky's attorneys access to high level company officials because it believed the documents would never be made public. They argued that releasing the documents now would betray that trust and bog down the state's civil court docket.
But Combs disagreed.
"The Court sees no higher value than the public (via the media) having access to these discovery materials so that the public can see the facts for themselves," he wrote.
Rick Berke, Statnews.com's executive editor, said in a news release that he was pleased the court moved swiftly to "bring to light records that can inform the public's understanding of Purdue's role in this crisis."
OxyContin had global sales of $2.5 billion in 2014, more than any other prescription painkiller. The Sackler family has made numerous philanthropic gifts over years, resulting in art museums that bear that family name at Harvard University and the Smithsonian in Washington.